<DOC>
	<DOCNO>NCT01948830</DOCNO>
	<brief_summary>This study design evaluate efficacy safety two different regimen 0.5 mg ranibizumab give intravitreal injection patient neovascular age-related macular degeneration</brief_summary>
	<brief_title>Randomized Study Efficacy Safety Ranibizumab 0.5mg Treat-extend Monthly Regimens Patients With nAMD</brief_title>
	<detailed_description>This 12-month , phase IIIb , randomize , Visual Acuity assessor-masked , multi-center , interventional study assess efficacy safety TER v monthly regimens 0.5 mg ranibizumab intravitreal ( IVT ) injection patient newly diagnose nAMD . Patients randomize 1:1 one two treatment arm , Treat Extend monthly regimen . There 3 period study : Screening period ( 14days ) , treatment period ( 11 month ) , follow-up period ( 1 month ) . At randomization visit patient randomize one 2 treatment group Group I ranibizumab 0.5 mg base monthly treatment Group II ranibizumab 0.5 mg base TER ( randomization ratio 1:1 ) receive first dose Investigational treatment . Patients Group I follow visit perform monthly interval . For patient Group II investigator evaluate disease activity ( i.e. , sign exudation ) base SD-OCT , case absence disease activity every next visit 2 week ) , maximum 12-week interval .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Key Male female patient , ≥50 year age sign informed consent study procedure Visual impairment predominantly due nAMD . Active CNV secondary AMD confirm presence active leakage CNV see fluorescein angiography ( FA ) and/or color fundus photography Presence intra subretinal fluid/hemorrhage see SDOCT BCVA score must ≤ 78 ≥ 23 letter 4 meter start distance use Early Treatment Diabetic Retinopathy Study ( ETDRS ) like visual acuity chart ( approximate Snellen equivalent 20/32 20/320 ) Key Any type advance , severe unstable disease , include medical condition ( control uncontrolled ) could expect progress , recur , change extent may bias assessment clinical status patient significant degree put patient special risk . Stroke myocardial infarction within 3 month prior Screening . Any active periocular ocular infection inflammation eye . Ocular disorder study eye time enrollment may confound interpretation study result compromise visual acuity . Presence amblyopia amaurosis fellow eye . History treatment antiangiogenic drug ( include anti vascular endothelial growth factor ( antiVEGF ) agent ) e.g. , bevacizumab [ Avastin® ] , aflibercept [ Eylea® ] ) vPDT study eye . History intravitreal treatment corticosteroid within 6 month history intraocular surgery within 3 month study eye prior Screening . Pregnant nursing ( lactate ) woman . Women childbearing potential , defined woman physiologically capable become pregnant , unless use effective method contraception dose study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Ranibizumab , Lucentis , choroidal neovascularization , age-related macular degeneration , treat extend regimen</keyword>
</DOC>